Ultragenyx Pharmaceutical Inc.
RARE
$33.47
$0.100.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -3.94% | 19.53% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.94% | 19.53% | |||
| Cost of Revenue | -85.09% | -3.44% | |||
| Gross Profit | 721.14% | 61.48% | |||
| SG&A Expenses | -0.03% | -1.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.57% | -2.78% | |||
| Operating Income | -58.40% | 24.52% | |||
| Income Before Tax | -57.49% | 23.88% | |||
| Income Tax Expenses | -7.81% | -27.71% | |||
| Earnings from Continuing Operations | -56.95% | 23.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -56.95% | 23.91% | |||
| EBIT | -58.40% | 24.52% | |||
| EBITDA | -63.48% | 25.89% | |||
| EPS Basic | -54.89% | 25.59% | |||
| Normalized Basic EPS | -56.01% | 25.49% | |||
| EPS Diluted | -54.89% | 25.59% | |||
| Normalized Diluted EPS | -56.01% | 25.49% | |||
| Average Basic Shares Outstanding | 1.33% | 2.26% | |||
| Average Diluted Shares Outstanding | 1.33% | 2.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||